Spark Therapeutics Expands Leadership Team to Support Development and Commercialization of its Late-Stage Gene Therapy Pipeline

    Spark Therapeutics Expands Leadership Team to Support Development and
          Commercialization of its Late-Stage Gene Therapy Pipeline

Joseph La Barge and Carol Greve-Philips expand business operations

PR Newswire

PHILADELPHIA, Jan. 9, 2014

PHILADELPHIA, Jan. 9, 2014 /PRNewswire/ --Spark Therapeutics, a late-stage,
fully integrated company developing gene-based medicines for a wide range of
debilitating diseases, announced todaythat it has expanded its leadership
team through the addition of two industry veterans, Joseph La Barge and Carol
Greve-Philips, who have extensive track records successfully growing biotech
businesses.

Joseph La Barge has joined Spark as senior vice president of business
administration and general counsel. Joe is a seasoned legal executive and
advisor, having provided counsel to healthcare institutions and biotechnology
and pharmaceutical companies for more than 15 years. Joe served as the vice
president, general counsel and chief compliance officer for Tengion, Inc., a
clinical-stage regenerative medicine company, where he had responsibility for
legal affairs, compliance and quality assurance. While at Tengion, he played
a critical role in developing the company's intellectual property strategies
for their novel, first-in-class, cell-based therapies. Over his career, Joe
has advised life science companies at all stages of development, structuring
over $800 million in private and public financings, developing intellectual
property strategies and building out biologic manufacturing space.

Carol Greve-Philips is joining the company as senior vice president of
business development and strategy. Carol comes to Spark with extensive
experience building, developing and restructuring businesses focused on
genetics, genomics and genetic testing. She worked for more than 15 years at
Genzyme Corporation in roles of increasing responsibility, serving most
recently as the vice president of corporate development. During her tenure at
Genzyme she contributed significantly to growing the Personal Genetic Health
Unit. Most recently she served as the chief business officer at Pronota NV, a
diagnostics company focused on early detection of heart failure, pre-eclampsia
and sepsis. 

"These appointments add tremendous depth to our already-stellar team of
leaders and advisors," said Jeffrey D. Marrazzo, co- founder, president and
chief executive officer of Spark Therapeutics. "Joe is uniquely qualified to
lead the rapid expansion of our operations as we work to complete the
development of our existing clinical programs and prepare to deliver our
groundbreaking treatments to patients, and Carol is an ideal counselor as we
consider opportunities for partnership and to expand our platform into other
diseases where single-dose therapies could transform patients' lives."

About Spark Therapeutics
Spark Therapeutics is developing potentially curative, one-time gene therapy
products to transform the lives of patients and re-imagine the treatment of
debilitating diseases. Spark's lead gene therapy candidate, for RPE65-related
blindness, is currently in Phase 3 clinical trials with the potential to be
the first approved gene therapy in the U.S., and the first treatment to
address the significant unmet needs of patients living with blindness due to
inherited retinal dystrophies.

Spark's founding team includes scientists who led the movement to develop gene
therapy as a new treatment paradigm, establishing clinical proof of concept in
the eye and liver and contributing key insights to the field that have
resulted in a resurgence of industry interest in gene-based medicines. In
addition to the Phase 3 program in RPE65-related blindness, the company has a
Phase 1/2 program in hemophilia B, and preclinical programs to address
neurodegenerative diseases and other inherited retinal dystrophies and
hematologic disorders. Spark has rights to a proprietary manufacturing
platform that has an unparalleled track record of success in supporting
clinical studies across diverse therapeutic areas and routes of
administration. The company's expertise across research, clinical, regulatory
and manufacturing builds on a legacy of innovation and excellence in gene
therapy established by Spark's team while at The Children's Hospital of
Philadelphia Center for Cellular and Molecular Therapeutics. To learn more
visit www.sparktx.com.

Media Inquiries:
Jessica Rowlands
202-729-4089
Jessica.Rowlands@fkhealth.com

SOURCE Spark Therapeutics

Website: http://www.sparktx.com